Actively Recruiting
Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions
Led by Wroclaw Medical University · Updated on 2026-06-01
400
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients hospitalized for acute cardiac conditions such as acute myocardial infarction, acute heart failure, pulmonary embolism, arrhythmias, and hypertensive emergencies face a high risk of repeated cardiovascular events. Influenza infection may trigger these adverse cardiac events. Despite evidence supporting influenza vaccination benefits in vulnerable cardiac patients, vaccination rates remain low. This trial explores whether giving the influenza vaccine within 24 hours before hospital discharge can reduce infections, cardiovascular events, and death during the following six months. The study is a randomized, open-label, single-center trial comparing two groups: one receiving standard care, including recommendations for influenza vaccination in primary care, and another receiving the influenza vaccine shortly before discharge. The vaccine will be administered prior to leaving the hospital. The research will evaluate safety and effectiveness over a six-month period after hospitalization. Participants will be monitored for infections, unplanned cardiovascular hospitalizations, and cardiovascular deaths during six months post-discharge. Researchers will track these outcomes to assess the impact of pre-discharge vaccination. The total participation period covers six months following hospital discharge, with assessments focusing on health events related to cardiac conditions and influenza infection.
CONDITIONS
Brief Title
Pre-discharge Influenza Vaccination in Patients Hospitalized for Acute Cardiac Conditions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acute cardiac hospitalization
- Planned discharge home within the next 48 hours following completion of in-hospital treatment
- No prior influenza vaccination for the current influenza season
You will not qualify if you...
- History of a severe adverse reaction to influenza vaccination
- Allergy to any component of the vaccine to be administered
- Discharge to another hospital for continuation of treatment or discharge to a long-term care facility
- Antibiotic therapy to be continued after discharge
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - Up to 48 hours before discharge
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) during hospitalization
Duration - Single day during hospital stay before discharge
Participants receive an influenza vaccination before hospital discharge or continue with standard care.
1 vaccination visit (in-person) prior to discharge
Duration - 6 months
Participants are monitored for infection, unplanned cardiovascular hospitalization, or cardiovascular death.
Follow-up contacts as scheduled by the study team
Trial Site Locations
Total: 1 location
1
Jan Mikulicz Radecki University Hospital in Wroclaw
Wroclaw, Poland, 50-556
Actively Recruiting
Research Team
P
Piotr Kübler Kübler, Professor
M
Michal Tkaczyszyn, M.D., PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here